FluoroPharma’s technology consists of novel molecular PET agents for the cardiovascular, oncology and neurology arenas.
The most advanced programs are in the area of cardiology where the agents have been designed to rapidly target either the myocardial cells within the heart or the vulnerable plaque within the coronary arteries. FluoroPharma’s proprietary molecules labeled with the radioactive isotope of fluorine [18F] combined with positron emission tomography (PET) scanning provide non-invasive, highly specific and efficient assessment of heart metabolism and physiology. Currently, FDG, mainly used in oncology, is the primary commercial [18F] labeled PET molecular imaging agent. FluoroPharma’s cardiovascular program targets the historically largest potential market of nuclear medicine, nuclear cardiology.
FluoroPharma’s broad technology platform was developed by scientists at the Massachusetts General Hospital and Harvard Medical School. The company has four issued US patents and seven pending applications in addition to strong international protection. Furthermore, the company actively pursues opportunities to license new PET technologies from individuals and institutions.